1
|
Diesler R, Legendre M, Si-Mohamed S, Brillet PY, Wemeau L, Manali ED, Gagnadoux F, Hirschi S, Lorillon G, Reynaud-Gaubert M, Bironneau V, Blanchard E, Bourdin A, Dominique S, Justet A, Macey J, Marchand-Adam S, Morisse-Pradier H, Nunes H, Papiris SA, Traclet J, Traore I, Crestani B, Amselem S, Nathan N, Borie R, Cottin V. Similarities and differences of interstitial lung disease associated with pathogenic variants in SFTPC and ABCA3 in adults. Respirology 2024; 29:312-323. [PMID: 38345107 DOI: 10.1111/resp.14667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2023] [Accepted: 01/21/2024] [Indexed: 03/19/2024]
Abstract
BACKGROUND AND OBJECTIVE Variants in surfactant genes SFTPC or ABCA3 are responsible for interstitial lung disease (ILD) in children and adults, with few studies in adults. METHODS We conducted a multicentre retrospective study of all consecutive adult patients diagnosed with ILD associated with variants in SFTPC or ABCA3 in the French rare pulmonary diseases network, OrphaLung. Variants and chest computed tomography (CT) features were centrally reviewed. RESULTS We included 36 patients (median age: 34 years, 20 males), 22 in the SFTPC group and 14 in the ABCA3 group. Clinical characteristics were similar between groups. Baseline median FVC was 59% ([52-72]) and DLco was 44% ([35-50]). An unclassifiable pattern of fibrosing ILD was the most frequent on chest CT, found in 85% of patients, however with a distinct phenotype with ground-glass opacities and/or cysts. Nonspecific interstitial pneumonia and usual interstitial pneumonia were the most common histological patterns in the ABCA3 group and in the SFTPC group, respectively. Annually, FVC and DLCO declined by 1.87% and 2.43% in the SFTPC group, respectively, and by 0.72% and 0.95% in the ABCA3 group, respectively (FVC, p = 0.014 and DLCO , p = 0.004 for comparison between groups). Median time to death or lung transplantation was 10 years in the SFTPC group and was not reached at the end of follow-up in the ABCA3 group. CONCLUSION SFTPC and ABCA3-associated ILD present with a distinct phenotype and prognosis. A radiologic pattern of fibrosing ILD with ground-glass opacities and/or cysts is frequently found in these rare conditions.
Collapse
Affiliation(s)
- Rémi Diesler
- Department of Respiratory Medicine, National Reference Centre for Rare Pulmonary Diseases, Hospices civils de Lyon, Université Lyon 1, UMR754, INRAE, ERN-LUNG, Lyon, France
| | - Marie Legendre
- U.F. de Génétique moléculaire, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Hôpital Armand Trousseau, Paris, France
- Childhood Genetic Diseases, UMR_S933, Inserm, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Hôpital Armand Trousseau, Paris, France
| | - Salim Si-Mohamed
- Department of Thoracic Imaging, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, INSA-Lyon, UJM-Saint-Étienne, CNRS, Inserm, CREATIS UMR 5220, Lyon, France
| | - Pierre-Yves Brillet
- Service de Radiologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
| | - Lidwine Wemeau
- CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Calmette, Lille, France
| | - Effrosyni D Manali
- 2nd Pulmonary Medicine Department, General University Hospital "Attikon," Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Frédéric Gagnadoux
- Service de Pneumologie et Allergologie, Centre Hospitalier Universitaire d'Angers, Angers, France
| | - Sandrine Hirschi
- Service de Pneumologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Gwenaël Lorillon
- National Reference Centre for Histiocytoses, Pulmonary Department, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
| | - Martine Reynaud-Gaubert
- Service de Pneumologie, Équipe de Transplantation Pulmonaire, Centre de Compétence des Maladies Pulmonaires Rares, Aix-Marseille Université, Assistance Publique-Hôpitaux de Marseille, CHU Nord, Marseille, France
| | - Vanessa Bironneau
- Service de Pneumologie CHU de Poitiers, INSERM CIC 1402, IS-ALIVE Research Group, Université de Poitiers, UFR Médecine et Pharmacie, Poitiers, France
| | - Elodie Blanchard
- Service de Pneumologie, Hôpital Haut Lévêque, CHU de Bordeaux, Bordeaux, France
| | - Arnaud Bourdin
- Department of Respiratory Diseases and PhyMedExp, Centre National de la Recherche Scientifique, INSERM, University of Montpellier, CHU Montpellier, Montpellier, France
| | | | - Aurélien Justet
- Service de Pneumologie, CHU de Caen, Centre de compétence des maladies pulmonaires rares, ISTCT, UMR6030-CNRS-CEA-Université de Caen, Caen, France
| | - Julie Macey
- Respiratory Medicine and Cystic Fibrosis Center, University Hospital Center of Bordeaux, Bordeaux, France
| | - Sylvain Marchand-Adam
- Service de Pneumologie et Explorations Fonctionnelles Respiratoires, CHU Tours, Université François Rabelais, Tours, France
| | | | - Hilario Nunes
- Service de Pneumologie et Oncologie Thoracique, Centre Constitutif Maladies Pulmonaires Rares de l'Adulte, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Paris, France
| | - Spyros A Papiris
- 2nd Pulmonary Medicine Department, General University Hospital "Attikon," Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Julie Traclet
- Department of Respiratory Medicine, National Reference Centre for Rare Pulmonary Diseases, Hospices civils de Lyon, Université Lyon 1, Lyon, France
| | - Ibrahim Traore
- Service de Pneumologie, CHU Jean Minjoz, Besançon, France
| | - Bruno Crestani
- Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Paris, France
| | - Serge Amselem
- U.F. de Génétique moléculaire, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Hôpital Armand Trousseau, Paris, France
- Childhood Genetic Diseases, UMR_S933, Inserm, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Hôpital Armand Trousseau, Paris, France
| | - Nadia Nathan
- Childhood Genetic Diseases, UMR_S933, Inserm, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Hôpital Armand Trousseau, Paris, France
- Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases and Laboratory of Childhood Genetic Diseases Inserm UMR_S933, Assistance Publique-Hôpitaux de Paris, Sorbonne University, Armand Trousseau Hospital, Paris, France
| | - Raphaël Borie
- Université Paris Cité, INSERM U1152, Laboratoire D'Excellence Inflamex, Assistance Publique-Hôpitaux de Paris, Service de Pneumologie A, Centre de Référence Constitutif des Maladies Pulmonaires Rares, Fédération Hospitalo-Universitaire Apollo, Hôpital Bichat, Paris, France
| | - Vincent Cottin
- Department of Respiratory Medicine, National Reference Centre for Rare Pulmonary Diseases, Hospices civils de Lyon, Université Lyon 1, UMR754, INRAE, ERN-LUNG, Lyon, France
| |
Collapse
|
2
|
Fetita C, Richeux J, Didier A, Maury M, Flint J, Brillet PY, Bergot E, Bernaudin JF, Justet A. Comparison between computerised lung SPECT-CT and noncontrast thoracic HRCT for quantitative analysis of post-acute COVID-19 pulmonary vascular pruning. ERJ Open Res 2023; 9:00076-2023. [PMID: 37868150 PMCID: PMC10588800 DOI: 10.1183/23120541.00076-2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Accepted: 08/09/2023] [Indexed: 10/24/2023] Open
Abstract
Computerised processing of images from routine noncontrast HRCT could be an efficient, costless and safe tool to investigate the vascular remodelling that occurs in the months after COVID-19 in a large number of patients https://bit.ly/3qAQZDW.
Collapse
Affiliation(s)
- Catalin Fetita
- SAMOVAR, Telecom SudParis, Institut Polytechnique de Paris, Evry, France
- These authors contributed equally
| | - Jean Richeux
- Service de Pneumologie, CHU de Caen, Caen, France
| | - Antoine Didier
- SAMOVAR, Telecom SudParis, Institut Polytechnique de Paris, Evry, France
| | - Mathilde Maury
- SAMOVAR, Telecom SudParis, Institut Polytechnique de Paris, Evry, France
| | - Jasper Flint
- Internal Medicine Department, Pulmonary Critical Care and Sleep Medicine Section, Yale School of Medicine, New Haven, CT, USA
| | - Pierre-Yves Brillet
- Service de Radiologie Hôpital Avicenne, AP-HP, Bobigny, France
- INSERM 1272 Université Sorbonne Paris-Nord, Bobigny, France
| | - Emmanuel Bergot
- Service de Pneumologie, CHU de Caen, Caen, France
- Université de Caen Normandie, CNRS, Normandie Université, ISTCT, UMR6030, GIP Cyceron, Caen, France
| | - Jean-Francois Bernaudin
- INSERM 1272 Université Sorbonne Paris-Nord, Bobigny, France
- Faculté de Médecine Sorbonne Université Paris, Paris, France
- These authors contributed equally
| | - Aurélien Justet
- Service de Pneumologie, CHU de Caen, Caen, France
- Internal Medicine Department, Pulmonary Critical Care and Sleep Medicine Section, Yale School of Medicine, New Haven, CT, USA
- Université de Caen Normandie, CNRS, Normandie Université, ISTCT, UMR6030, GIP Cyceron, Caen, France
- These authors contributed equally
| |
Collapse
|
3
|
Liu Y, Li N, Qi J, Xu G, Zhao J, Wang N, Huang X, Jiang W, Justet A, Adams TS, Homer R, Amei A, Rosas IO, Kaminski N, Wang Z, Yan X. A hybrid machine learning and regression method for cell type deconvolution of spatial barcoding-based transcriptomic data. bioRxiv 2023:2023.08.24.554722. [PMID: 37662370 PMCID: PMC10473707 DOI: 10.1101/2023.08.24.554722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
Spatial barcoding-based transcriptomic (ST) data require cell type deconvolution for cellular-level downstream analysis. Here we present SDePER, a hybrid machine learning and regression method, to deconvolve ST data using reference single-cell RNA sequencing (scRNA-seq) data. SDePER uses a machine learning approach to remove the systematic difference between ST and scRNA-seq data (platform effects) explicitly and efficiently to ensure the linear relationship between ST data and cell type-specific expression profile. It also considers sparsity of cell types per capture spot and across-spots spatial correlation in cell type compositions. Based on the estimated cell type proportions, SDePER imputes cell type compositions and gene expression at unmeasured locations in a tissue map with enhanced resolution. Applications to coarse-grained simulated data and four real datasets showed that SDePER achieved more accurate and robust results than existing methods, suggesting the importance of considering platform effects, sparsity and spatial correlation in cell type deconvolution.
Collapse
|
4
|
Marchal-Duval E, Homps-Legrand M, Froidure A, Jaillet M, Ghanem M, Lou D, Justet A, Maurac A, Vadel A, Fortas E, Cazes A, Joannes A, Giersh L, Mal H, Mordant P, Piolot T, Truchin M, Mounier CM, Schirduan K, Korfei M, Gunther A, Mari B, Jaschinski F, Crestani B, Mailleux AA. Identification of paired-related Homeobox Protein 1 as a key mesenchymal transcription factor in pulmonary fibrosis. eLife 2023; 12:79840. [PMID: 37261432 DOI: 10.7554/elife.79840] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Accepted: 05/31/2023] [Indexed: 06/02/2023] Open
Abstract
Matrix remodeling is a salient feature of idiopathic pulmonary fibrosis (IPF). Targeting cells driving matrix remodeling could be a promising avenue for IPF treatment. Analysis of transcriptomic database identified the mesenchymal transcription factor PRRX1 as upregulated in IPF. PRRX1, strongly expressed by lung fibroblasts, was regulated by a TGF-b/PGE2 balance in vitro in control and IPF human lung fibroblasts, while IPF fibroblast-derived matrix increased PRRX1 expression in a PDGFR dependent manner in control ones. PRRX1 inhibition decreased human lung fibroblast proliferation by downregulating the expression of S phase cyclins. PRRX1 inhibition also impacted TGF-β driven myofibroblastic differentiation by inhibiting SMAD2/3 phosphorylation through phosphatase PPM1A upregulation and TGFBR2 downregulation, leading to TGF-β response global decrease. Finally, targeted inhibition of Prrx1 attenuated fibrotic remodeling in vivo with intra-tracheal antisense oligonucleotides in bleomycin mouse model of lung fibrosis and ex vivo using human and mouse precision-cut lung slices. Our results identified PRRX1 as a key mesenchymal transcription factor during lung fibrogenesis.
Collapse
Affiliation(s)
- Emmeline Marchal-Duval
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Méline Homps-Legrand
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Antoine Froidure
- Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium
| | - Madeleine Jaillet
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Mada Ghanem
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Deneuville Lou
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Aurélien Justet
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Arnaud Maurac
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Aurelie Vadel
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Emilie Fortas
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Aurelie Cazes
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Audrey Joannes
- Institut de recherche en santé, environnement et travail, Univ Rennes, Inserm, EHESP, Rennes, France
| | - Laura Giersh
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Herve Mal
- Service de Pneumologie et Transplantation, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Pierre Mordant
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| | - Tristan Piolot
- Collège de France, CNRS-UMR7241, INSERM-U1050, PSL Research University,, Paris, France
| | | | | | | | - Martina Korfei
- Department of Internal Medicine II, University of Giessen, Gießen, Germany
| | - Andreas Gunther
- Department of Internal Medicine, University of Giessen, Gießen, Germany
| | | | | | - Bruno Crestani
- Service de Pneumologie, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Arnaud A Mailleux
- Physiopathologie et épidémiologie des maladies respiratoires, Université Paris Cité, Inserm, Paris, France
| |
Collapse
|
5
|
Ghanem M, Archer G, Justet A, Hachem M, Boghanim T, Vadel A, Poté N, Cazes A, Mordant P, Castier Y, Mal H, Jaillet M, Mailleux A, Crestani B. Effet protecteur du FGF21 endogène et exogène dans la fibrose pulmonaire. Rev Mal Respir 2023. [DOI: 10.1016/j.rmr.2022.11.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
|
6
|
Justet A, Ghanem M, Boghanim T, Hachem M, Vasarmidi E, Jaillet M, Vadel A, Joannes A, Mordant P, Bonniaud P, Kolb M, Ling L, Cazes A, Mal H, Mailleux A, Crestani B. FGF19 is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice. Am J Respir Cell Mol Biol 2022; 67:173-187. [PMID: 35549849 DOI: 10.1165/rcmb.2021-0246oc] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
IPF is a devastating lung disease with limited therapeutic possibilities. FGF19, an endocrine FGF, was recently shown to decrease liver fibrosis. To ask whether FGF19 had anti-fibrotic properties in the lung and decipher its effects on common features associated with lung fibrogenesis. We assessed, by Elisa, FGF19 levels in plasma and bronchoalveolar lavage fluids (BALF)obtained from controls and IPF patients. In vivo, using an intravenously administered adeno11 associated virus (AAV), we overexpressed FGF19 at the fibrotic phase of two experimental models of murine lung fibrosis and assessed its effect on lung morphology, lung collagen content, fibrosis markers and pro fibrotic mediator expression, at mRNA and protein levels. In vitro, we investigated whether FGF19 could modulate the TGFβ-induced differentiation of primary human lung fibroblast into myofibroblast and the apoptosis of murine alveolar type II cell. While FGF19 was not detected in BALF, FGF19 concentration was decreased in the plasma of IPF patients compared to controls. In vivo, the overexpression of FGF19 was associated with a marked decrease of lung fibrosis and fibrosis markers, with a decrease of pro fibrotic mediator expression and lung collagen content. In vitro, FGF19 decreased alveolar type 2 epithelial cell apoptosis through the decrease of the proapoptotic BIM protein expression and prevented TGF-ß induced myofibroblast differentiation through the inhibition of JNK phosphorylation. Altogether these data identify FGF19 as an anti-fibrotic molecule with a potential therapeutic interest in fibrotic lung disorders.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Audrey Joannes
- INSERM U1085, IRSET Institut de Recherche sur la Santé, l'Environnement et le Travail, Université de Rennes-1, Rennes, France
| | - Pierre Mordant
- Assistance Publique - Hopitaux de Paris, 26930, Bichat Hospital, Department of Vascular and Thoracic Sugery, Paris, France.,INSERM, U1152, Paris, France.,Universite Paris Diderot UFR de Medecine Site Xavier-Bichat, 60152, Paris, France
| | - Philippe Bonniaud
- CHU Dijon-Bourgogne, Service de Pneumologie et Soins Intensifs Respiratoires, Dijon, France
| | - Martin Kolb
- McMaster University, Hamilton, Ontario, Canada
| | - Lei Ling
- NGM Biopharmaceuticals Inc, 200841, San Francisco, California, United States
| | | | | | - Arnaud Mailleux
- Inserm U700, Faculté de Médecine Paris 7, site X. Bichat, Paris, France
| | - Bruno Crestani
- AP-HP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Université Paris Diderot, Paris, France;
| |
Collapse
|
7
|
Deshayes S, Leite Ferreira D, Madelaine J, Oulkhouir Y, Campbell K, Fouquet H, Teulier S, Magnier R, Heyndrickx M, Lerouge D, Bergot E, Justet A. [D-CBP study: Evaluation of lung cancer management times]. Rev Mal Respir 2021; 38:894-903. [PMID: 34756617 DOI: 10.1016/j.rmr.2021.09.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2021] [Accepted: 07/28/2021] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Lung cancer is the leading cause of cancer-related death. Delays may have an impact on patient survival. The objective of this study was to evaluate the diagnostic and therapeutic management times for patients admitted for lung cancer treatment in the Respiratory Department of CHU de Caen Normandie. MATERIALS AND METHODS This is a retrospective, single-center and observational study, conducted on all patients treated for lung cancer from June 2017 to January 2018 in our department of pneumology in the Caen Normandie CHU. The main median times were investigated were: Global Time (abnormal imaging-treatment), Diagnosis time (abnormal imaging-diagnosis) and Treatment Time (diagnosis-treatment). RESULTS One hundred and twenty-seven (127) patients were included. Median global time was 55.5 days [31,25; 393], median diagnosis time was 22 days [13; 49], and median treatment time was 24.5 days [12,25; 45]. DISCUSSION Our treatment times are consistent with those previously published. Areas for improvement are being developed in accordance with the 2014-2019 cancer plan, in particularly the creation in our institution of a specific care pathway for patients with lung cancer.
Collapse
Affiliation(s)
- S Deshayes
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - D Leite Ferreira
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - J Madelaine
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - Y Oulkhouir
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - K Campbell
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - H Fouquet
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - S Teulier
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - R Magnier
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France
| | - M Heyndrickx
- Service de Chirurgie Thoracique, CHU de Caen, 14000 Caen, France
| | - D Lerouge
- Service de Radiothérapie, Centre de Lutte contre le Cancer François Baclesse, 14000 Caen, France
| | - E Bergot
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France; ISTCT, UMR6030-CNRS-CEA-Université de Caen, 14000 Caen, France
| | - A Justet
- Service de Pneumologie et d'Oncologie Thoracique, CHU de Caen, 14000 Caen, France; ISTCT, UMR6030-CNRS-CEA-Université de Caen, 14000 Caen, France.
| |
Collapse
|
8
|
Justet A, Klay D, Porcher R, Cottin V, Ahmad K, Molina Molina M, Nunes H, Reynaud-Gaubert M, Naccache JM, Manali E, Froidure A, Jouneau S, Wemeau L, Andrejak C, Gondouin A, Hirschi S, Blanchard E, Bondue B, Bonniaud P, Tromeur C, Prévot G, Marchand-Adam S, Funke-Chambour M, Gamez AS, Ba I, Papiris S, Grutters J, Crestani B, van Moorsel C, Kannengiesser C, Borie R. Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. Eur Respir J 2021; 57:13993003.03198-2020. [PMID: 33214205 DOI: 10.1183/13993003.03198-2020] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2020] [Accepted: 09/09/2020] [Indexed: 11/05/2022]
Affiliation(s)
- Aurélien Justet
- Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.,OrphaLung Network, Paris, France.,Center for rare pulmonary disease, Service de Pneumologie, CHU de Caen - ISTCT, UMR6030-CNRS-CEA-Université de Caen, Caen, France
| | - Dymph Klay
- Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
| | - Raphaël Porcher
- Centre of Research in Epidemiology and Statistics Sorbonne Paris Cité -CRESS-UMR1153, Paris, France
| | - Vincent Cottin
- OrphaLung Network, Paris, France.,National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France
| | - Kais Ahmad
- OrphaLung Network, Paris, France.,National reference center for rare pulmonary diseases (OrphaLung), Dept of Respiratory Medicine, Louis Pradel Hospital; UMR754, Claude Bernard Lyon 1 University; Lyon, France
| | - Maria Molina Molina
- Unit of Interstitial Lung Diseases, Dept of Pneumology, University Hospital of Bellvitge, Barcelona, Spain
| | - Hilario Nunes
- OrphaLung Network, Paris, France.,Reference center for rare pulmonary diseases APHP, Service de Pneumologie, Hôpital Avicenne, Bobigny, France
| | - Martine Reynaud-Gaubert
- OrphaLung Network, Paris, France.,Center for rare pulmonary disease, Service de Pneumologie, Hôpital Nord, Marseille, France
| | - Jean Marc Naccache
- OrphaLung Network, Paris, France.,Reference center for rare pulmonary diseases, APHP, Service de Pneumologie, Hôpital Tenon, Paris, France
| | - Effrosyni Manali
- Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Antoine Froidure
- Cliniques Universitaires Saint-Luc, Service de Pneumologie, Bruxelles, France
| | - Stéphane Jouneau
- OrphaLung Network, Paris, France.,Center for rare pulmonary disease, Centre Hospitalier Universitaire de Rennes, Service de Pneumologie, - IRSET (Institut de recherche en santé, environnement et travail) - UMR_S 1085, Université de Rennes 1, Rennes, France
| | - Lidwine Wemeau
- OrphaLung Network, Paris, France.,Reference center for rare pulmonary diseases, Service de Pneumologie, CHRU de Lille, Lille, France
| | - Claire Andrejak
- OrphaLung Network, Paris, France.,Center for rare pulmonary disease, Service de Pneumologie, Hôpital d'Amiens, Université de Picardie Jules Verne, Amiens, France
| | - Anne Gondouin
- OrphaLung Network, Paris, France.,Center for rare pulmonary disease CHU de Besançon, Service de Pneumologie, Besançon, France
| | - Sandrine Hirschi
- OrphaLung Network, Paris, France.,Center for rare pulmonary disease, Service de Pneumologie, Groupe de Transplantation Pulmonaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Elodie Blanchard
- OrphaLung Network, Paris, France.,Center for rare pulmonary disease, CHU de Bordeaux, Service de Pneumologie, Pessac, France
| | | | - Philippe Bonniaud
- OrphaLung Network, Paris, France.,Reference center for rare pulmonary diseases, Service de Pneumologie, Dijon, France
| | - Cécile Tromeur
- OrphaLung Network, Paris, France.,CHU de la Cavale Blanche, Département de médecine interne et de pneumologie, Brest, France
| | - Grégoire Prévot
- OrphaLung Network, Paris, France.,Center for rare pulmonary diseases, Service de Pneumologie, Hôpital Larrey, Toulouse, France
| | - Sylvain Marchand-Adam
- OrphaLung Network, Paris, France.,Center for rare pulmonary diseases, CHU de Tours, Service de Pneumologie et Explorations Fonctionnelles Respiratoires, Tours, France
| | | | - Anne Sophie Gamez
- OrphaLung Network, Paris, France.,Center for rare pulmonary diseases, Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHU Montpellier, Montpellier, France
| | - Ibrahima Ba
- OrphaLung Network, Paris, France.,Dept of Genetics, APHP, Hôpital Bichat, Paris, France
| | - Spyridon Papiris
- Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Jan Grutters
- Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
| | - Bruno Crestani
- Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.,OrphaLung Network, Paris, France
| | - Coline van Moorsel
- Interstitial Lung Diseases Center of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands
| | | | - Raphaël Borie
- Université de Paris, Reference center for rare pulmonary diseases, Service de Pneumologie A, Bichat Hospital, DHU APOLLO, APHP - Paris (France) - INSERM UMR 1152, Paris, France.,OrphaLung Network, Paris, France
| | | |
Collapse
|
9
|
Deshayes S, Magnier R, Rault F, Teulier S, Fouquet H, Bergot E, Justet A. Lesson of the month: management for aspiration of a silver nitrate pencil tip during tracheostomy care. Thorax 2021; 76:632-633. [PMID: 33514669 DOI: 10.1136/thoraxjnl-2020-215727] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2020] [Revised: 12/07/2020] [Accepted: 12/12/2020] [Indexed: 11/03/2022]
Abstract
We present the cases of two laryngectomised patients who were treated for granulomas of the tracheostomy orifice with a silver nitrate pencil. During tracheostomy care, the tip broke off, was aspirated and fell into the bronchial tree. Necrotising ulcerative injuries of the right bronchial tree with clear delineation were found without lesions in the subsegmental division. To prevent the risk of secondary stenosis of the small airways induced by the spread of silver nitrate, we did not irrigate with saline solution as previously reported. Antibiotherapy and endoscopic monitoring were performed. Complete healing in 4-6 weeks was found without stenosis of the bronchial tree or bleeding.
Collapse
Affiliation(s)
- Simon Deshayes
- Service de Pneumologie et d'Oncologie Thoracique, CHU Caen, Caen, France
| | - Romain Magnier
- Service de Pneumologie et d'Oncologie Thoracique, CHU Caen, Caen, France
| | - Frédérick Rault
- Service d'ORL et de chirurgie cervico-faciale, CHU Caen, Caen, France
| | - Sylvain Teulier
- Service de Pneumologie et d'Oncologie Thoracique, CHU Caen, Caen, France
| | - Helen Fouquet
- Service de Pneumologie et d'Oncologie Thoracique, CHU Caen, Caen, France
| | - Emmanuel Bergot
- Service de Pneumologie et d'Oncologie Thoracique, CHU Caen, Caen, France.,ISTCT, UMR6030-CNRS-CEA-Université de Caen, Caen, France
| | - Aurélien Justet
- Service de Pneumologie et d'Oncologie Thoracique, CHU Caen, Caen, France .,ISTCT, UMR6030-CNRS-CEA-Université de Caen, Caen, France
| |
Collapse
|
10
|
Froidure A, Marchal-Duval E, Homps-Legrand M, Ghanem M, Justet A, Crestani B, Mailleux A. Chaotic activation of developmental signalling pathways drives idiopathic pulmonary fibrosis. Eur Respir Rev 2020; 29:29/158/190140. [PMID: 33208483 DOI: 10.1183/16000617.0140-2019] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2020] [Accepted: 05/25/2020] [Indexed: 12/28/2022] Open
Abstract
Idiopathic pulmonary fibrosis (IPF) is characterised by an important remodelling of lung parenchyma. Current evidence indicates that the disease is triggered by alveolar epithelium activation following chronic lung injury, resulting in alveolar epithelial type 2 cell hyperplasia and bronchiolisation of alveoli. Signals are then delivered to fibroblasts that undergo differentiation into myofibroblasts. These changes in lung architecture require the activation of developmental pathways that are important regulators of cell transformation, growth and migration. Among others, aberrant expression of profibrotic Wnt-β-catenin, transforming growth factor-β and Sonic hedgehog pathways in IPF fibroblasts has been assessed. In the present review, we will discuss the transcriptional integration of these different pathways during IPF as compared with lung early ontogeny. We will challenge the hypothesis that aberrant transcriptional integration of these pathways might be under the control of a chaotic dynamic, meaning that a small change in baseline conditions could be sufficient to trigger fibrosis rather than repair in a chronically injured lung. Finally, we will discuss some potential opportunities for treatment, either by suppressing deleterious mechanisms or by enhancing the expression of pathways involved in lung repair. Whether developmental mechanisms are involved in repair processes induced by stem cell therapy will also be discussed.
Collapse
Affiliation(s)
- Antoine Froidure
- Institut National de la Santé et de la Recherche Médical, UMR1152, Labex Inflamex, DHU FIRE, Université de Paris, Faculté de médecine Xavier Bichat, Paris, France.,Institut de Recherche Expérimentale et Clinique, Pôle de Pneumologie, Université catholique de Louvain, Belgium Service de pneumologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - Emmeline Marchal-Duval
- Institut National de la Santé et de la Recherche Médical, UMR1152, Labex Inflamex, DHU FIRE, Université de Paris, Faculté de médecine Xavier Bichat, Paris, France
| | - Meline Homps-Legrand
- Institut National de la Santé et de la Recherche Médical, UMR1152, Labex Inflamex, DHU FIRE, Université de Paris, Faculté de médecine Xavier Bichat, Paris, France
| | - Mada Ghanem
- Institut National de la Santé et de la Recherche Médical, UMR1152, Labex Inflamex, DHU FIRE, Université de Paris, Faculté de médecine Xavier Bichat, Paris, France.,Assistance Publique des Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France
| | - Aurélien Justet
- Institut National de la Santé et de la Recherche Médical, UMR1152, Labex Inflamex, DHU FIRE, Université de Paris, Faculté de médecine Xavier Bichat, Paris, France.,Assistance Publique des Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France.,Service de pneumologie, CHU de Caen, Caen, France
| | - Bruno Crestani
- Institut National de la Santé et de la Recherche Médical, UMR1152, Labex Inflamex, DHU FIRE, Université de Paris, Faculté de médecine Xavier Bichat, Paris, France.,Assistance Publique des Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France
| | - Arnaud Mailleux
- Institut National de la Santé et de la Recherche Médical, UMR1152, Labex Inflamex, DHU FIRE, Université de Paris, Faculté de médecine Xavier Bichat, Paris, France
| |
Collapse
|
11
|
Daubin C, Justet A, Vabret A, Bergot E, Terzi N. Is a COPD patient protected against SARS-CoV-2 virus? Infect Dis Now 2020; 51:98-99. [PMID: 33022292 PMCID: PMC7532759 DOI: 10.1016/j.medmal.2020.09.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 08/20/2020] [Accepted: 09/24/2020] [Indexed: 01/16/2023]
Affiliation(s)
- C Daubin
- Department of Medical Intensive Care, CHU de Caen, 14000 Caen, France.
| | - A Justet
- Department of Pulmonology & Thoracic Oncology, CHU de Caen, 14000 Caen, France
| | - A Vabret
- Department of Virology, CHU de Caen, 14000 Caen, France
| | - E Bergot
- Department of Pulmonology & Thoracic Oncology, CHU de Caen, 14000 Caen, France
| | - N Terzi
- Department of Medical Intensive Care, CHU de Grenoble-Alpes, 38000 Grenoble, France
| |
Collapse
|
12
|
Jeny F, Lhote R, Lorillon G, Belhomme N, Pugnet G, Borie R, Justet A, Jouneau S, Freymond N, Mekinian A, Dhote R, Tandjaoui-Lambiotte Y, Saindenberg N, Gazengel P, Hervier B, Haroche J, Mathian A, Hié M, Chazal T, Taieb D, Uzunhan Y, Le Pavec J, Annesi-Maesano I, Bergot E, Tazi A, Amoura Z, Valeyre D, Nunes H, Cohen-Aubart F. Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'. Ann Rheum Dis 2020; 81:e241. [PMID: 33004334 DOI: 10.1136/annrheumdis-2020-218957] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2020] [Accepted: 08/26/2020] [Indexed: 12/19/2022]
Affiliation(s)
- Florence Jeny
- Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
| | - Raphael Lhote
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Gwenael Lorillon
- Service de Pneurmologie, Assistance Publique Hôpitaux de Paris, Hopital Saint-Louis, Paris, France
| | - Nicolas Belhomme
- Département de Médecine Interne et Immunologie Clinique, CHU Rennes, Rennes, France
| | - Grégory Pugnet
- UMR1027, Service de Médecine Interne, INSERM et CHU de Toulouse, Toulouse, France.,Service de Médecine Interne, CHU Toulouse, Toulouse, France
| | - Raphaël Borie
- Service de Pneumologie, Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Paris, France
| | - Aurélien Justet
- Service de Pneumologie, CHU Caen, Caen, Basse-Normandie, France
| | | | | | - Arsène Mekinian
- Service de Médecine Interne, DHUi2B, Assistance Publique Hôpitaux de Paris, Hôpital Saint-Antoine, Paris, France
| | - Robin Dhote
- Service de Médecine Interne, Assitance Publique Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
| | | | | | - Pierre Gazengel
- Service de Pneumologie, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France
| | - Baptiste Hervier
- Service de Médecine Interne, Assitance Publique Hôpitaux de Paris, Hôpital Saint Louis, Paris, France
| | - Julien Haroche
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Alexis Mathian
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Miguel Hié
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Thibaud Chazal
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Dov Taieb
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Yurdagul Uzunhan
- Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
| | - Jérôme Le Pavec
- Service de Pneumologie, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France
| | | | | | - Abdellatif Tazi
- Service de Pneurmologie, Assistance Publique Hôpitaux de Paris, Hopital Saint-Louis, Paris, France
| | - Zahir Amoura
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| | - Dominique Valeyre
- Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
| | - Hilario Nunes
- Service de Pneumologie, Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Bobigny, France
| | - Fleur Cohen-Aubart
- Sorbonne Université, Service de Médecine Interne 2, maladies auto-immunes et systémiques, Assitance Publique Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Paris, France
| |
Collapse
|
13
|
Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N, Justet A. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis 2020; 79:1381-1382. [PMID: 32376597 DOI: 10.1136/annrheumdis-2020-217706] [Citation(s) in RCA: 171] [Impact Index Per Article: 42.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 04/28/2020] [Accepted: 04/28/2020] [Indexed: 01/16/2023]
Affiliation(s)
- Achille Aouba
- Department of Internal Medicine and Clinical Immunology, CHU Caen, Caen, France
| | | | - Loïk Geffray
- Department of Internal Medicine and Clinical Immunology, CH Lisieux, Lisieux, France
| | - Renaud Verdon
- Department of Infectious Diseases, CHU Caen, Caen, France
| | | | | | | |
Collapse
|
14
|
Bègne C, Justet A, Dupin C, Taillé C. Evaluation in a severe asthma expert center improves asthma outcomes regardless of step-up in asthma therapy. J Allergy Clin Immunol Pract 2019; 8:1439-1442.e2. [PMID: 31706047 DOI: 10.1016/j.jaip.2019.10.026] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Received: 05/08/2019] [Revised: 10/08/2019] [Accepted: 10/14/2019] [Indexed: 01/29/2023]
Affiliation(s)
- Camille Bègne
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Groupe Hospitalier Universitaire AP-HP Nord- Université de Paris, Paris, France
| | - Aurélien Justet
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Groupe Hospitalier Universitaire AP-HP Nord- Université de Paris, Paris, France; INSERM UMR 1152, LabEx Inflamex, Paris, France
| | - Clairelyne Dupin
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Groupe Hospitalier Universitaire AP-HP Nord- Université de Paris, Paris, France
| | - Camille Taillé
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Groupe Hospitalier Universitaire AP-HP Nord- Université de Paris, Paris, France; INSERM UMR 1152, LabEx Inflamex, Paris, France.
| |
Collapse
|
15
|
Tabèze L, Marchand-Adam S, Borie R, Justet A, Dupin C, Dombret MC, Crestani B, Taillé C. Severe asthma with blood hypereosinophilia associated with JAK2 V617F mutation: a case series. Eur Respir J 2019; 53:13993003.02248-2018. [PMID: 31000675 DOI: 10.1183/13993003.02248-2018] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2019] [Accepted: 03/03/2019] [Indexed: 12/11/2022]
Affiliation(s)
- Laure Tabèze
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
| | - Sylvain Marchand-Adam
- Département de Pneumologie et Explorations fonctionnelles respiratoires, Centre Hopitalo Universitaire de Tours, Tours, France.,INSERM U-1100, Faculté de médecine, Université François Rabelais, Tours, France
| | - Raphaël Borie
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
| | - Aurélien Justet
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
| | - Clairelyne Dupin
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
| | - Marie-Christine Dombret
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
| | - Bruno Crestani
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
| | - Camille Taillé
- Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Département Hospitalo-Universitaire FIRE, Université Paris Diderot, INSERM UMR 1152, LabEx Inflamex, Paris, France
| |
Collapse
|
16
|
Justet A, Klay D, Cottin V, Nunes H, Molina Molina M, Reynaud-Gaubert M, Naccache J, Manali E, Froidure A, Wemeau L, Gondouin A, Bonniaud P, Andrejak C, Hirschi S, Stéphane J, Tromeur C, Prevost G, Marchand-Adam S, Gamez A, Kannengiesser C, Van Moorsel C, Crestani B, Borie R. Efficacité et tolérance des traitements anti-fibrosants chez les patients porteurs d’une mutation du complexe telomèrase. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
17
|
Justet A, Boghanim T, Jaillet M, Fortas E, Mailleux A, Crestani B. Implication du récepteur FGFR4 et de ses ligands dans la Fibrose Pulmonaire Idiopathique. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Justet A, Thabut G, Manali E, Molina Molina M, Kannengiesser C, Cadranel J, Cottin V, Gondouin A, Nunes H, Magois E, Tromeur C, Prevot G, Papiris S, Marchand-Adam S, Gamez AS, Reynaud-Gaubert M, Wemeau L, Crestani B, Borie R. Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. Eur Respir J 2018; 51:13993003.01875-2017. [PMID: 29449422 DOI: 10.1183/13993003.01875-2017] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Accepted: 01/04/2018] [Indexed: 11/05/2022]
Affiliation(s)
- Aurélien Justet
- APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France.,INSERM, Unité 1152, Université Paris Diderot, Paris, France
| | - Gabriel Thabut
- INSERM, Unité 1152, Université Paris Diderot, Paris, France.,APHP, Hôpital Bichat, Service de Pneumologie B, Paris, France
| | - Effrosyni Manali
- Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Maria Molina Molina
- Unit of Interstitial Lung Diseases, Dept of Pneumology, University Hospital of Bellvitge, Barcelona, Spain
| | | | - Jacques Cadranel
- APHP, Service de Pneumologie, maladies pulmonaires rares, Hôpital Tenon, Paris, France
| | - Vincent Cottin
- Service de Pneumologie, Hôpital Louis Pradel, Université Claude Bernard Lyon 1, Lyon, France
| | - Anne Gondouin
- CHU de Besançon, Service de Pneumologie, Besançon, France
| | - Hilario Nunes
- APHP, Service de Pneumologie, maladies pulmonaires rares, Hôpital Avicenne, Bobigny, France
| | - Eline Magois
- Service de Pneumologie, Hôpital d'Amiens, Université de Picardie Jules Verne, Amiens, France
| | - Cécile Tromeur
- Université Européenne de Bretagne, UBO, EA3878 (GETBO) IFR 148, CHU de la Cavale Blanche, Département de médecine interne et de pneumologie, Brest, France
| | | | - Spyros Papiris
- Respiratory Medicine Dept, 'Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece
| | - Sylvain Marchand-Adam
- CHU de Tours, Service de Pneumologie et Explorations Fonctionnelles Respiratoires, Tours, France
| | - Anne Sophie Gamez
- Département de Pneumologie et Addictologie, Hôpital Arnaud de Villeneuve, CHU Montpellier, Montpellier, France
| | | | | | - Bruno Crestani
- APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France.,INSERM, Unité 1152, Université Paris Diderot, Paris, France
| | - Raphael Borie
- APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France .,INSERM, Unité 1152, Université Paris Diderot, Paris, France
| |
Collapse
|
19
|
Menou A, Flajolet P, Duitman J, Justet A, Moog S, Jaillet M, Tabèze L, Solhonne B, Garnier M, Mal H, Mordant P, Castier Y, Cazes A, Sallenave J, A. Mailleux A, Crestani B. Human airway trypsin‐like protease exerts potent, antifibrotic action in pulmonary fibrosis. FASEB J 2018; 32:1250-1264. [DOI: 10.1096/fj.201700583r] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Awen Menou
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - Pauline Flajolet
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - JanWillem Duitman
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - Aurélien Justet
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Service de Pneumologie A Assistance Publique‐Hôpitaux de Paris (AP‐HP), Hôpital Bichat Paris France
| | - Sophie Moog
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - Madeleine Jaillet
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - Laure Tabèze
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Service de Pneumologie A Assistance Publique‐Hôpitaux de Paris (AP‐HP), Hôpital Bichat Paris France
| | - Brigitte Solhonne
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - Marc Garnier
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Departement d'Anesthésie et Réanimation, (AP‐HP) Hôpital Tenon Paris France
| | - Hervé Mal
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Service de Pneumologie et Transplantation Assistance Publique‐Hôpitaux de Paris (AP‐HP), Hôpital Bichat Paris France
| | - Pierre Mordant
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Service de Chirurgie Thoracique et Vasculaire Assistance Publique‐Hôpitaux de Paris (AP‐HP), Hôpital Bichat Paris France
| | - Yves Castier
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Service de Chirurgie Thoracique et Vasculaire Assistance Publique‐Hôpitaux de Paris (AP‐HP), Hôpital Bichat Paris France
| | - Aurélie Cazes
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Departement d'Anatomie Pathologique Assistance Publique‐Hôpitaux de Paris (AP‐HP), Hôpital Bichat Paris France
| | - Jean‐Michel Sallenave
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - Arnaud A. Mailleux
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
| | - Bruno Crestani
- INSERM, Unité 1552 Paris France
- Département Hospitalo‐Universitaire Fibrosis, Inflammation, and Remodeling in Renal and Respiratory Diseases (FIRE) Paris France
- Laboratoire d'Excellence Inflamex Paris France
- Université Paris Diderot, Sorbonne Paris Cité Paris France
- Service de Pneumologie A Assistance Publique‐Hôpitaux de Paris (AP‐HP), Hôpital Bichat Paris France
| |
Collapse
|
20
|
Beltramo G, Thabut G, Peron N, Nicaise P, Cazes A, Debray MP, Joannes A, Castier Y, Mailleux AA, Frija J, Pradère P, Justet A, Borie R, Dombret MC, Taille C, Aubier M, Crestani B. Anti-parietal cell autoimmunity is associated with an accelerated decline of lung function in IPF patients. Respir Med 2018; 135:15-21. [PMID: 29414448 DOI: 10.1016/j.rmed.2017.12.011] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 11/26/2017] [Accepted: 12/26/2017] [Indexed: 12/27/2022]
Abstract
BACKGROUND Autoantibodies against lung epithelial antigens are often detected in patients with Idiopathic Pulmonary Fibrosis (IPF). Anti-Parietal Cell Antibodies (APCA) target the H+/K+ATPase (proton pump). APCA prevalence and lung H+/K+ATPase expression was never studied in IPF patients. METHODS We retrospectively collected clinical, lung function and imaging data from APCA positive patients (APCA+IPF) and compared them with APCA negative IPF patients matched on the date of diagnostic assessment. H+/K+ATPase expression was assessed with immunohistochemistry and PCR. RESULTS Among 138 IPF patients diagnosed between 2007 and 2014 and tested for APCA, 19 (13.7%) APCA+ patients were identified. APCA+IPF patients were 16 men and 3 women, mean age 71 years. The median titer of APCA was 1:160. A pernicious anemia was present in 5 patients and preceded the fibrosis in 3 cases. With a mean follow up of 31 months, 2 patients had an exacerbation and 7 patients died. As compared with 19 APCA- IPF patients, APCA+IPF patients had a less severe disease with better DLCO (57% vs 43% predicted), preserved PaO2 (85 ± 8 mmHg vs 74 ± 11 mmHg), a lower rate of honeycombing on HRCT (58% vs 89%), but they experienced an accelerated decline of FVC (difference 61.4 ml/year; p = .0002). The H+/K+ATPase was strongly expressed by hyperplastic alveolar epithelial cells in the fibrotic lung. CONCLUSION Anti-parietal cell autoimmunity is detected in some IPF patients and is associated with an accelerated decline of lung function. Anti-parietal cell autoimmunity may promote lung fibrosis progression.
Collapse
Affiliation(s)
- Guillaume Beltramo
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France
| | - Gabriel Thabut
- Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie et Transplantation, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Nicolas Peron
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France
| | - Pascale Nicaise
- Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Département d'Hématologie et Immunologie UF Autoimmunité et Hypersensibilités, 75018 Paris, France
| | - Aurélie Cazes
- INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Département d'Anatomie Pathologique, 75018 Paris, France
| | - Marie-Pierre Debray
- Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Radiologie, Paris, France
| | - Audrey Joannes
- INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Yves Castier
- INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Chirurgie Vasculaire et Thoracique 75018 Paris, France
| | - Arnaud A Mailleux
- INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Justine Frija
- Université Paris Diderot, Paris, France; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service d'Explorations Fonctionnelles Multidisciplinaires, 75018 Paris, France
| | - Pauline Pradère
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France
| | - Aurélien Justet
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Raphaël Borie
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Marie-Christine Dombret
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Camille Taille
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Michel Aubier
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France
| | - Bruno Crestani
- Assistance Publique-Hôpitaux de Paris, DHU FIRE (Fibrosis, Inflammation and Remodeling), Hôpital Bichat, Service de Pneumologie A, 75018 Paris, France; INSERM UMR 1152, Labex Inflamex, Paris, France; Université Paris Diderot, Paris, France.
| |
Collapse
|
21
|
Tabèze L, Marchand-Adam S, Dupin C, Justet A, Dombret M, Borie R, Crestani B, Taille C. Présence d’une mutation de JAK2 au cours d’un asthme hyperéosinophile. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
22
|
Justet A, Joannes A, Besnard V, Marchal-Sommé J, Jaillet M, Bonniaud P, Sallenave JM, Solhonne B, Castier Y, Mordant P, Mal H, Cazes A, Borie R, Mailleux AA, Crestani B. FGF9 prevents pleural fibrosis induced by intrapleural adenovirus injection in mice. Am J Physiol Lung Cell Mol Physiol 2017; 313:L781-L795. [PMID: 28729349 DOI: 10.1152/ajplung.00508.2016] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2016] [Revised: 07/10/2017] [Accepted: 07/10/2017] [Indexed: 12/12/2022] Open
Abstract
Fibroblast growth factor 9 (FGF9) is necessary for fetal lung development and is expressed by epithelium and mesothelium. We evaluated the role of FGF9 overexpression on adenoviral-induced pleural injury in vivo and determined the biological effects of FGF9 on mesothelial cells in vitro. We assessed the expression of FGF9 and FGF receptors by mesothelial cells in both human and mouse lungs. Intrapleural injection of an adenovirus expressing human FGF9 (AdFGF9) or a control adenovirus (AdCont) was performed. Mice were euthanized at days 3, 5, and 14 Expression of FGF9 and markers of inflammation and myofibroblastic differentiation was studied by qPCR and immunohistochemistry. In vitro, rat mesothelial cells were stimulated with FGF9 (20 ng/ml), and we assessed its effect on proliferation, survival, migration, and differentiation. FGF9 was expressed by mesothelial cells in human idiopathic pulmonary fibrosis. FGF receptors, mainly FGFR3, were expressed by mesothelial cells in vivo in humans and mice. AdCont instillation induced diffuse pleural thickening appearing at day 5, maximal at day 14 The altered pleura cells strongly expressed α-smooth muscle actin and collagen. AdFGF9 injection induced maximal FGF9 expression at day 5 that lasted until day 14 FGF9 overexpression prevented pleural thickening, collagen and fibronectin accumulation, and myofibroblastic differentiation of mesothelial cells. In vitro, FGF9 decreased mesothelial cell migration and inhibited the differentiating effect of transforming growth factor-β1. We conclude that FGF9 has a potential antifibrotic effect on mesothelial cells.
Collapse
Affiliation(s)
- Aurélien Justet
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie A, Paris, France
| | - Audrey Joannes
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Valérie Besnard
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Joëlle Marchal-Sommé
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Madeleine Jaillet
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Philipe Bonniaud
- Institut National de la Santé et de la Recherche Médicale U866, Université de Bourgogne, Dijon, France
| | - Jean Michel Sallenave
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Brigitte Solhonne
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Yves Castier
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Chirurgie Thoracique et Vasculaire, Paris, France
| | - Pierre Mordant
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Chirurgie Thoracique et Vasculaire, Paris, France
| | - Hervé Mal
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie et Transplantation, Paris, France; and
| | - Aurélie Cazes
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Département d'Anatomie Pathologique, Paris, France
| | - Raphael Borie
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie A, Paris, France
| | - Arnaud A Mailleux
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France.,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Bruno Crestani
- Institut National de la Santé et de la Recherche Médicale U1152, Paris, France; .,Département Hospitalo-Universitaire Fibrosis Inflammation and Remodeling (DHU FIRE), Paris, France.,Labex Inflamex, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Service de Pneumologie A, Paris, France
| |
Collapse
|
23
|
Juge PA, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, Debray MP, Ottaviani S, Marchand-Adam S, Nathan N, Thabut G, Richez C, Nunes H, Callebaut I, Justet A, Leulliot N, Bonnefond A, Salgado D, Richette P, Desvignes JP, Lioté H, Froguel P, Allanore Y, Sand O, Dromer C, Flipo RM, Clément A, Béroud C, Sibilia J, Coustet B, Cottin V, Boissier MC, Wallaert B, Schaeverbeke T, Dastot le Moal F, Frazier A, Ménard C, Soubrier M, Saidenberg N, Valeyre D, Amselem S, Boileau C, Crestani B, Dieudé P. Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. Eur Respir J 2017; 49:49/5/1602314. [PMID: 28495692 DOI: 10.1183/13993003.02314-2016] [Citation(s) in RCA: 124] [Impact Index Per Article: 17.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Accepted: 02/11/2017] [Indexed: 11/05/2022]
Abstract
Despite its high prevalence and mortality, little is known about the pathogenesis of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Given that familial pulmonary fibrosis (FPF) and RA-ILD frequently share the usual pattern of interstitial pneumonia and common environmental risk factors, we hypothesised that the two diseases might share additional risk factors, including FPF-linked genes. Our aim was to identify coding mutations of FPF-risk genes associated with RA-ILD.We used whole exome sequencing (WES), followed by restricted analysis of a discrete number of FPF-linked genes and performed a burden test to assess the excess number of mutations in RA-ILD patients compared to controls.Among the 101 RA-ILD patients included, 12 (11.9%) had 13 WES-identified heterozygous mutations in the TERT, RTEL1, PARN or SFTPC coding regions. The burden test, based on 81 RA-ILD patients and 1010 controls of European ancestry, revealed an excess of TERT, RTEL1, PARN or SFTPC mutations in RA-ILD patients (OR 3.17, 95% CI 1.53-6.12; p=9.45×10-4). Telomeres were shorter in RA-ILD patients with a TERT, RTEL1 or PARN mutation than in controls (p=2.87×10-2).Our results support the contribution of FPF-linked genes to RA-ILD susceptibility.
Collapse
Affiliation(s)
- Pierre-Antoine Juge
- APHP, Hôpital Bichat, Service de Rhumatologie, DHU FIRE, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,These authors contributed equally
| | - Raphaël Borie
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France.,INSERM U1152, Paris, France.,These authors contributed equally
| | - Caroline Kannengiesser
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,APHP, Service de Génétique, Hôpital Bichat, Paris, France.,INSERM, UMR_1149 Centre de Recherches sur l'Inflammation Paris, Paris, France.,These authors contributed equally
| | - Steven Gazal
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,INSERM, IAME, UMR_1137, Paris, France.,APHP, Plateforme de génomique constitutionnelle du GHU Nord, Hôpital Bichat, Paris, France
| | - Patrick Revy
- INSERM UMR_1163, Laboratory of Genome Dynamics in the Immune System, Institut Imagine, Paris, France.,Université Paris Descartes, Sorbonne Cité, Paris, France
| | - Lidwine Wemeau-Stervinou
- CHRU de Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence maladies pulmonaires rares, FHU IMMINENT, Lille, France.,Université Lille 2, Lille, France
| | - Marie-Pierre Debray
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,APHP, Hôpital Bichat, Service de Radiologie, Paris, France
| | - Sébastien Ottaviani
- APHP, Hôpital Bichat, Service de Rhumatologie, DHU FIRE, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Sylvain Marchand-Adam
- CHRU Tours, Service de Pneumologie, Tours, France.,Université Francois Rabelais, Tours, France.,INSERM, U1100, Tours, France
| | - Nadia Nathan
- APHP, Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France.,INSERM UMR_S933, Paris, France.,Université Pierre et Marie Curie, Sorbonne Paris Cité, Paris, France
| | - Gabriel Thabut
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,INSERM U1152, Paris, France.,APHP, Hôpital Bichat, Service de Pneumologie B, DHU FIRE, Paris, France
| | - Christophe Richez
- CHU de Bordeaux, service de rhumatologie, Bordeaux, France.,Immuno ConcEpT, CNRS UMR_5164, Bordeaux, France.,Université de Bordeaux, Bordeaux, France
| | - Hilario Nunes
- AP-HP, Hôpital Avicenne, Service de Pneumologie, Bobigny, France.,Université Paris 13, Sorbonne Paris Cité, Paris, France
| | - Isabelle Callebaut
- Université Pierre et Marie Curie, Sorbonne Paris Cité, Paris, France.,CNRS UMR_7590, MNHM-IRD-IUC, Paris, France
| | - Aurélien Justet
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France
| | - Nicolas Leulliot
- Université Paris Descartes, Sorbonne Cité, Paris, France.,Laboratoire de Cristallographie et RMN Biologiques, UMR CNRS 8015, Faculté de Pharmacie, Paris, France
| | - Amélie Bonnefond
- Université Lille 2, Lille, France.,CNRS, UMR_8199, Lille, France.,European Genomic Institute for Diabetes, Lille, France
| | - David Salgado
- Aix-Marseille Université, GMGF, Marseille, France.,INSERM, UMR_S 910, Marseille, France
| | - Pascal Richette
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,AP-HP, hôpital Lariboisière, Service de Rhumatologie, Paris, France.,INSERM, UMR_1132, Paris, France
| | - Jean-Pierre Desvignes
- Aix-Marseille Université, GMGF, Marseille, France.,INSERM, UMR_S 910, Marseille, France
| | - Huguette Lioté
- APHP, Hôpital Tenon, Service de Pneumologie, Paris, France
| | - Philippe Froguel
- Université Lille 2, Lille, France.,CNRS, UMR_8199, Lille, France.,Dept of Genomics of Common Diseases, School of Public Health, Imperial College London, Hammersmith Hospital, London, UK
| | - Yannick Allanore
- Université Paris Descartes, Sorbonne Cité, Paris, France.,APHP, Hôpital Cochin, Service de Rhumatologie A, Paris, France.,INSERM, U1016, UMR_8104, Paris, France
| | - Olivier Sand
- Université Lille 2, Lille, France.,CNRS, UMR_8199, Lille, France.,European Genomic Institute for Diabetes, Lille, France
| | - Claire Dromer
- Université de Bordeaux, Bordeaux, France.,CHU de Bordeaux, Service d'Imagerie Thoracique et Cardiovasculaire, Pessac, France
| | - René-Marc Flipo
- Université Lille 2, Lille, France.,CHU de Lille, Service de Rhumatologie, Lille, France
| | - Annick Clément
- APHP, Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France.,INSERM UMR_S933, Paris, France.,Université Pierre et Marie Curie, Sorbonne Paris Cité, Paris, France
| | - Christophe Béroud
- Aix-Marseille Université, GMGF, Marseille, France.,INSERM, UMR_S 910, Marseille, France.,APHM, Hôpital La Timone Enfants, Laboratoire de Génétique Moléculaire, Marseille, France
| | - Jean Sibilia
- CHRU de Strasbourg, Service de Rhumatologie, Hôpital de Hautepierre, Strasbourg, France.,INSERM UMR_S1109, Laboratoire d'Immuno-Rhumatologie Moléculaire, CRHI, FMTS, Université de Strasbourg, Strasbourg, France.,Fédération Hospitalo-Universitaire OMICARE, Strasbourg, France
| | - Baptiste Coustet
- APHP, Hôpital Bichat, Service de Rhumatologie, DHU FIRE, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Vincent Cottin
- Hospices Civils de Lyon, Hôpital Louis Pradel, Centre national de référence des maladies pulmonaires rares, Lyon, France.,INRA, UMR_754, Université Claude Bernard Lyon 1, Lyon, France
| | - Marie-Christophe Boissier
- Université Paris 13, Sorbonne Paris Cité, Paris, France.,INSERM U1125, Bobigny, France.,APHP, GH HUPSSD, Service de Rhumatologie, Bobigny, France
| | - Benoit Wallaert
- CHRU de Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence maladies pulmonaires rares, FHU IMMINENT, Lille, France.,Université Lille 2, Lille, France
| | - Thierry Schaeverbeke
- CHU de Bordeaux, service de rhumatologie, Bordeaux, France.,Immuno ConcEpT, CNRS UMR_5164, Bordeaux, France.,Université de Bordeaux, Bordeaux, France
| | - Florence Dastot le Moal
- APHP, Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France.,Université Pierre et Marie Curie, Sorbonne Paris Cité, Paris, France.,APHP, Département de Génétique, Hôpital Trousseau, Paris, France
| | - Aline Frazier
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,AP-HP, hôpital Lariboisière, Service de Rhumatologie, Paris, France
| | - Christelle Ménard
- APHP, Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France.,INSERM UMR_S933, Paris, France.,Université Pierre et Marie Curie, Sorbonne Paris Cité, Paris, France
| | - Martin Soubrier
- CHU Clermont-Ferrand, Service de Rhumatologie, INRA, UMR1019, UNH, CRNH Auvergne, Clermont-Ferrand, France
| | - Nathalie Saidenberg
- Université Paris 13, Sorbonne Paris Cité, Paris, France.,APHP, GH HUPSSD, Service de Rhumatologie, Bobigny, France
| | - Dominique Valeyre
- AP-HP, Hôpital Avicenne, Service de Pneumologie, Bobigny, France.,Université Paris 13, Sorbonne Paris Cité, Paris, France
| | - Serge Amselem
- APHP, Service de Pneumologie Pédiatrique et Centre de référence des maladies respiratoires rares, Hôpital Trousseau, Paris, France.,INSERM UMR_S933, Paris, France.,APHP, Département de Génétique, Hôpital Trousseau, Paris, France
| | | | - Catherine Boileau
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,APHP, Service de Génétique, Hôpital Bichat, Paris, France.,INSERM, UMR_1148, Maladies structurelles cardiovasculaires, Paris, France
| | - Bruno Crestani
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Paris, France.,INSERM U1152, Paris, France
| | - Philippe Dieudé
- APHP, Hôpital Bichat, Service de Rhumatologie, DHU FIRE, Paris, France .,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.,INSERM, UMR_1149 Centre de Recherches sur l'Inflammation Paris, Paris, France
| |
Collapse
|
24
|
Justet A, Laurent-Bellue A, Thabut G, Dieudonné A, Debray MP, Borie R, Aubier M, Lebtahi R, Crestani B. [ 18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res 2017; 18:74. [PMID: 28449678 PMCID: PMC5408423 DOI: 10.1186/s12931-017-0556-3] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2016] [Accepted: 04/18/2017] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a devastating disease characterized by an unpredictable course. Prognostic markers and disease activity markers are needed. The purpose of this single-center retrospective study was to evaluate the prognostic value of lung fluorodeoxyglucose ([18F]-FDG) uptake assessed by standardized uptake value (SUV), metabolic lung volume (MLV) and total lesion glycolysis (TLG) in patients with IPF. METHODS We included 27 IPF patients (IPF group) and 15 patients with a gastrointestinal neuroendocrine tumor without thoracic involvement (control group). We quantified lung SUV mean and SUV max, MLV and TLG and assessed clinical data, high-resolution CT (HRCT) fibrosis and ground-glass score; lung function; gender, age, physiology (GAP) stage at inclusion and during follow-up; and survival. RESULTS Lung SUV mean and SUV max were higher in IPF patients than controls (p <0.00001). For patients with IPF, SUV mean, SUV max, MLV and TLG were correlated with severity of lung involvement as measured by a decline in forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) and increased GAP score. In a univariate and in a multivariate Cox proportional-hazards model, risk of death was increased although not significantly with high SUV mean. On univariate analysis, risk of death was significantly associated with high TLG and MLV, which disappeared after adjustment functional variables or GAP index. Increased MLV and TLG were independent predictors of death or disease progression during the 12 months after PET scan completion (for every 100-point increase in TLG, hazard ratio [HR]: 1.11 (95% CI 1.06; 1.36), p = 0.003; for every 100-point increase in MLV, HR: 1.20 (1.04; 1.19), p = 0.002). On multivariable analysis including TLG or MLV with age, FVC, and DLCO or GAP index, TLG and MLV remained associated with progression-free survival (HR: 1.1 [1.03; 1.22], p = 0.01; and 1.13 [1.0; 1.2], p = 0.005). CONCLUSION FDG lung uptake may be a marker of IPF severity and predict progression-free survival for patients with IPF.
Collapse
Affiliation(s)
- Aurélien Justet
- APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Centre de compétence des maladies pulmonaires rares, 46 rue Henri Huchard, 75018, Paris, France. .,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
| | | | - Gabriel Thabut
- APHP, Hôpital Bichat, Service de Pneumologie et de Transplantation Pulmonaire, DHU FIRE, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Arnaud Dieudonné
- APHP, Hôpital Beaujon Service de Médecine nucléaire, Clichy, France
| | | | - Raphael Borie
- APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Centre de compétence des maladies pulmonaires rares, 46 rue Henri Huchard, 75018, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Michel Aubier
- APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Centre de compétence des maladies pulmonaires rares, 46 rue Henri Huchard, 75018, Paris, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Rachida Lebtahi
- APHP, Hôpital Beaujon Service de Médecine nucléaire, Clichy, France.,Université Paris Diderot, Sorbonne Paris Cité, Paris, France
| | - Bruno Crestani
- APHP, Hôpital Bichat, Service de Pneumologie A, DHU FIRE, Centre de compétence des maladies pulmonaires rares, 46 rue Henri Huchard, 75018, Paris, France. .,Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
| |
Collapse
|
25
|
Juge P, Borie R, Kannengiesser C, Gazal S, Revy P, Wemeau-Stervinou L, Debray M, Ottaviani S, Marchand-Adam S, Nathan N, Thabut G, Richez C, Nunes H, Callebaut I, Justet A, Leulliot N, Bonnefond A, Salgado D, Richette P, Desvignes J, Lioté H, Froguel P, Allanore Y, Sand O, Dromer C, Flipo R, Clément A, Béroud C, Sibilia J, Coustet B, Cottin V, Boissier M, Wallaert B, Schaeverbeke T, Moal FDL, Frazier A, Ménard C, Soubrier M, Saidenberg N, Valeyre D, Amselem S, Boileau C, Crestani B, Dieude P. Fond génétique partagé entre la pneumopathie interstitielle diffuse associée à la polyarthrite rhumatoïde et la fibrose pulmonaire idiopathique. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
26
|
Justet A, Laurent-Bellue A, Thabut G, Debray M, Borie R, Lebtahi R, Crestani B. Le TLG mesuré par le TEP scanner est un facteur prédictif indépendant de survie sans progression dans la FPI. Rev Mal Respir 2017. [DOI: 10.1016/j.rmr.2016.10.306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
27
|
Beltramo G, Peron N, Nicaise P, Danel C, Debray M, Pradère P, Justet A, Borie R, Dombret M, Taille C, Aubier M, Crestani B. Pneumopathie interstitielle idiopathique et auto-immunité muqueuse anti-cellules pariétales gastriques. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
28
|
Justet A, Pradère P, Taillé C. [Current and prospective issues about adult asthma]. Rev Mal Respir 2015; 32:629-38. [PMID: 26163989 DOI: 10.1016/j.rmr.2015.01.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Accepted: 12/12/2014] [Indexed: 11/17/2022]
Abstract
The management of asthma treatment is likely to change in coming years, with the development of a more personalized approach. Biological therapies targeting Th2 cytokines (IL-4, IL-5 and IL-13) offer new treatment pathways for patients with severe asthma and high Th2 activity. Bronchial thermoplasty is the only treatment for severe asthma that could provide a long standing effect, but many questions still remain and its use is restricted to clinical research. Weight loss should be a goal during long-term management of obese asthmatics. Involvement of a new inflammatory pathway including IL-1 and IL-17 in a murine model of obesity and asthma may lead to new therapies in this subgroup of asthmatics.
Collapse
Affiliation(s)
- A Justet
- Service de pneumologie et centre de compétence pour les maladies pulmonaires rares, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris cedex 18, France
| | - P Pradère
- Service de pneumologie et centre de compétence pour les maladies pulmonaires rares, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris cedex 18, France
| | - C Taillé
- Service de pneumologie et centre de compétence pour les maladies pulmonaires rares, hôpital Bichat, 46, rue Henri-Huchard, 75877 Paris cedex 18, France.
| |
Collapse
|
29
|
Justet A, Joannes A, Marchal-Somme J, Besnard V, Bellaye PS, Bonniaud P, Mailleux A, Crestani B. Le FGF-9 inhibe la fibrose pleurale viro-induite chez la souris. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
30
|
Justet A, Laurent-Bellue A, Debray MP, Borie R, Lebtahi R, Thabut G, Aubier M, Crestani B. Intérêt pronostique du TEP au 18F-FDG dans la fibrose pulmonaire idiopathique. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
31
|
Justet A, Joannes A, Marchal-Somme J, Besnard V, Bellaye P, Bonniaud P, Mailleux A, Crestani B. Le FGF-9 inhibe la fibrose pleurale viro-induite chez la souris. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2014.10.716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
32
|
Justet A, Neukirch C, Poubeau P, Arrault X, Borie R, Dombret MC, Crestani B. Successful rapid tocilizumab desensitization in a patient with Still disease. The Journal of Allergy and Clinical Immunology: In Practice 2014; 2:631-2. [DOI: 10.1016/j.jaip.2014.04.015] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/12/2014] [Revised: 04/24/2014] [Accepted: 04/28/2014] [Indexed: 10/25/2022]
|